CA2385228A1 - Ribozymes pour la prevention de la restenose - Google Patents
Ribozymes pour la prevention de la restenose Download PDFInfo
- Publication number
- CA2385228A1 CA2385228A1 CA002385228A CA2385228A CA2385228A1 CA 2385228 A1 CA2385228 A1 CA 2385228A1 CA 002385228 A CA002385228 A CA 002385228A CA 2385228 A CA2385228 A CA 2385228A CA 2385228 A1 CA2385228 A1 CA 2385228A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- sequence seq
- seq
- rna molecule
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000037803 restenosis Diseases 0.000 title claims abstract description 14
- 108090000994 Catalytic RNA Proteins 0.000 title description 105
- 102000053642 Catalytic RNA Human genes 0.000 title description 105
- 108091092562 ribozyme Proteins 0.000 title description 105
- 230000002265 prevention Effects 0.000 title description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 109
- 102000003909 Cyclin E Human genes 0.000 claims abstract description 54
- 108090000257 Cyclin E Proteins 0.000 claims abstract description 54
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 claims abstract description 33
- 102100024026 Transcription factor E2F1 Human genes 0.000 claims abstract description 33
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims description 80
- 238000003776 cleavage reaction Methods 0.000 claims description 13
- 230000007017 scission Effects 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 102000053602 DNA Human genes 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract description 6
- 230000022131 cell cycle Effects 0.000 abstract description 4
- 108090001102 Hammerhead ribozyme Proteins 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 241000251131 Sphyrna Species 0.000 description 16
- 230000003197 catalytic effect Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 102100034343 Integrase Human genes 0.000 description 7
- 101710203526 Integrase Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000031481 Pathologic Constriction Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108010063774 E2F1 Transcription Factor Proteins 0.000 description 1
- 102000015699 E2F1 Transcription Factor Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003144 traumatizing effect Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Molécule d'ARN à action catalytique, qui est dirigée contre des molécules d'ARNm codant pour les protéines cycline E ou E2F1 pertinentes pour le cycle cellulaire. Ladite molécule d'ARN à action catalytique est un ribozyme en tête de marteau qui induit l'inhibition du cycle cellulaire de cellules vasculaires de muscles lisses pour prévenir la resténose.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP1999/007049 WO2001021789A1 (fr) | 1999-09-22 | 1999-09-22 | Ribozymes pour la prevention de la restenose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385228A1 true CA2385228A1 (fr) | 2001-03-29 |
Family
ID=8167447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385228A Abandoned CA2385228A1 (fr) | 1999-09-22 | 1999-09-22 | Ribozymes pour la prevention de la restenose |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1214408A1 (fr) |
| JP (1) | JP2003535573A (fr) |
| CA (1) | CA2385228A1 (fr) |
| WO (1) | WO2001021789A1 (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
-
1999
- 1999-09-22 JP JP2001525347A patent/JP2003535573A/ja active Pending
- 1999-09-22 CA CA002385228A patent/CA2385228A1/fr not_active Abandoned
- 1999-09-22 WO PCT/EP1999/007049 patent/WO2001021789A1/fr not_active Application Discontinuation
- 1999-09-22 EP EP99948829A patent/EP1214408A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001021789A1 (fr) | 2001-03-29 |
| EP1214408A1 (fr) | 2002-06-19 |
| JP2003535573A (ja) | 2003-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5066095B2 (ja) | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 | |
| Schubert et al. | Ribozyme-and deoxyribozyme-strategies for medical applications | |
| Morris | siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code | |
| JP5383186B2 (ja) | Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法 | |
| Marschall et al. | Inhibition of gene expression with ribozymes | |
| JPH1052264A (ja) | Ｎ‐ｒａｓ発現阻害剤およびその方法 | |
| Grassi et al. | Therapeutic potential of hammerhead ribozymes in the treatment of hyper-proliferative diseases | |
| CA2232738C (fr) | Strategie pour la suppression de l'expression de genes endogenes | |
| EP1147189A2 (fr) | Ribozymotherapie destinee au traitement et/ou a la prevention de la restenose | |
| Sioud | Nucleic acid enzymes as a novel generation of anti-gene agents | |
| Hübinger et al. | Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells | |
| WO2008099396A1 (fr) | Utilisation d'agents à base d'acides nucléiques réduisant h19 au silence pour traiter la resténose | |
| CA2380678A1 (fr) | Traitement d'affections inflammatoires et malignes | |
| Prasad et al. | Therapeutic targets in telomerase and telomere biology of cancers | |
| Osako et al. | Increase in nuclease resistance and incorporation of NF‐κB decoy oligodeoxynucleotides by modification of the 3′‐terminus | |
| CA2385228A1 (fr) | Ribozymes pour la prevention de la restenose | |
| Prins et al. | Antisense of oligonucleotides and the inhibition of oncogene expression | |
| Gibson | Antisense DNA and RNA strategies: new approaches to therapy | |
| JP4505566B2 (ja) | 肺癌治療剤 | |
| Phylactou et al. | Potential therapy paradigms for Marfan syndrome | |
| EP0951540A2 (fr) | Acides nucleiques antisens et ribozymes a tete de marteau | |
| Lavrovsky et al. | Ribozyme Technology and Drug Development | |
| WO2012131673A2 (fr) | Agents de type acides nucléiques inactivant le ccat-1 pour traiter le cancer | |
| WO2009024763A2 (fr) | Thérapie par combinaison | |
| WO2004046356A1 (fr) | Exon 1$g(b) du gene $g(a) du recepteur du pdgf et son utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |